nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—uterine cancer	0.216	1	CrCtD
Epirubicin—Anthracyclines—Doxorubicin—uterine cancer	0.124	0.427	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Etoposide—uterine cancer	0.102	0.35	CiPCiCtD
Epirubicin—ovarian cancer—uterine cancer	0.0831	0.556	CtDrD
Epirubicin—sarcoma—uterine cancer	0.0663	0.444	CtDrD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—uterine cancer	0.0649	0.223	CiPCiCtD
Epirubicin—Valrubicin—Doxorubicin—uterine cancer	0.0457	0.333	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—uterine cancer	0.0457	0.333	CrCrCtD
Epirubicin—Daunorubicin—Doxorubicin—uterine cancer	0.0457	0.333	CrCrCtD
Epirubicin—AURKA—Doxorubicin—uterine cancer	0.0292	0.225	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—uterine cancer	0.0292	0.225	CbGbCtD
Epirubicin—DHCR7—Doxorubicin—uterine cancer	0.0292	0.225	CbGbCtD
Epirubicin—ABCC1—Progesterone—uterine cancer	0.0108	0.0831	CbGbCtD
Epirubicin—TOP2A—Etoposide—uterine cancer	0.00871	0.0671	CbGbCtD
Epirubicin—ABCC1—Dactinomycin—uterine cancer	0.00855	0.0659	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—uterine cancer	0.00594	0.0457	CbGbCtD
Epirubicin—ABCC1—Etoposide—uterine cancer	0.00483	0.0372	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—uterine cancer	0.00329	0.0254	CbGbCtD
Epirubicin—CHD1—myometrium—uterine cancer	0.000589	0.0365	CbGeAlD
Epirubicin—AURKA—myometrium—uterine cancer	0.000474	0.0294	CbGeAlD
Epirubicin—CHD1—uterine cervix—uterine cancer	0.000458	0.0284	CbGeAlD
Epirubicin—CHD1—decidua—uterine cancer	0.000436	0.0271	CbGeAlD
Epirubicin—CHD1—endometrium—uterine cancer	0.000414	0.0257	CbGeAlD
Epirubicin—Doxorubicin—AKR1C3—uterine cancer	0.000412	1	CrCbGaD
Epirubicin—CHD1—mammalian vulva—uterine cancer	0.000401	0.0249	CbGeAlD
Epirubicin—CHD1—uterus—uterine cancer	0.000382	0.0237	CbGeAlD
Epirubicin—AURKA—uterine cervix—uterine cancer	0.000369	0.0229	CbGeAlD
Epirubicin—YWHAG—myometrium—uterine cancer	0.000364	0.0226	CbGeAlD
Epirubicin—AURKA—renal system—uterine cancer	0.000345	0.0214	CbGeAlD
Epirubicin—CHD1—female reproductive system—uterine cancer	0.000343	0.0213	CbGeAlD
Epirubicin—AURKA—endometrium—uterine cancer	0.000334	0.0207	CbGeAlD
Epirubicin—AURKA—mammalian vulva—uterine cancer	0.000323	0.02	CbGeAlD
Epirubicin—CHD1—female gonad—uterine cancer	0.000312	0.0194	CbGeAlD
Epirubicin—CHD1—vagina—uterine cancer	0.00031	0.0193	CbGeAlD
Epirubicin—DHCR7—uterine cervix—uterine cancer	0.000309	0.0192	CbGeAlD
Epirubicin—AURKA—uterus—uterine cancer	0.000308	0.0191	CbGeAlD
Epirubicin—YWHAG—uterine cervix—uterine cancer	0.000283	0.0176	CbGeAlD
Epirubicin—AURKA—female reproductive system—uterine cancer	0.000277	0.0172	CbGeAlD
Epirubicin—YWHAG—smooth muscle tissue—uterine cancer	0.000275	0.0171	CbGeAlD
Epirubicin—PLA2G4A—myometrium—uterine cancer	0.000272	0.0169	CbGeAlD
Epirubicin—DHCR7—mammalian vulva—uterine cancer	0.00027	0.0168	CbGeAlD
Epirubicin—YWHAG—decidua—uterine cancer	0.00027	0.0168	CbGeAlD
Epirubicin—YWHAG—renal system—uterine cancer	0.000265	0.0164	CbGeAlD
Epirubicin—TOP2A—myometrium—uterine cancer	0.000258	0.016	CbGeAlD
Epirubicin—YWHAG—endometrium—uterine cancer	0.000256	0.0159	CbGeAlD
Epirubicin—AURKA—female gonad—uterine cancer	0.000252	0.0156	CbGeAlD
Epirubicin—AURKA—vagina—uterine cancer	0.00025	0.0155	CbGeAlD
Epirubicin—YWHAG—mammalian vulva—uterine cancer	0.000248	0.0154	CbGeAlD
Epirubicin—UGT2B7—renal system—uterine cancer	0.000239	0.0149	CbGeAlD
Epirubicin—YWHAG—uterus—uterine cancer	0.000236	0.0147	CbGeAlD
Epirubicin—DHCR7—female reproductive system—uterine cancer	0.000231	0.0144	CbGeAlD
Epirubicin—YWHAG—female reproductive system—uterine cancer	0.000212	0.0132	CbGeAlD
Epirubicin—PLA2G4A—uterine cervix—uterine cancer	0.000211	0.0131	CbGeAlD
Epirubicin—DHCR7—female gonad—uterine cancer	0.000211	0.0131	CbGeAlD
Epirubicin—DHCR7—vagina—uterine cancer	0.000209	0.013	CbGeAlD
Epirubicin—PLA2G4A—smooth muscle tissue—uterine cancer	0.000205	0.0127	CbGeAlD
Epirubicin—PLA2G4A—decidua—uterine cancer	0.000201	0.0125	CbGeAlD
Epirubicin—TOP2A—uterine cervix—uterine cancer	0.000201	0.0125	CbGeAlD
Epirubicin—CHD1—lymph node—uterine cancer	0.000201	0.0125	CbGeAlD
Epirubicin—PLA2G4A—renal system—uterine cancer	0.000198	0.0123	CbGeAlD
Epirubicin—YWHAG—female gonad—uterine cancer	0.000193	0.012	CbGeAlD
Epirubicin—YWHAG—vagina—uterine cancer	0.000192	0.0119	CbGeAlD
Epirubicin—UGT2B7—female reproductive system—uterine cancer	0.000192	0.0119	CbGeAlD
Epirubicin—TOP2A—decidua—uterine cancer	0.000191	0.0119	CbGeAlD
Epirubicin—PLA2G4A—endometrium—uterine cancer	0.000191	0.0119	CbGeAlD
Epirubicin—PLA2G4A—mammalian vulva—uterine cancer	0.000185	0.0115	CbGeAlD
Epirubicin—TOP2A—endometrium—uterine cancer	0.000182	0.0113	CbGeAlD
Epirubicin—TOP2A—mammalian vulva—uterine cancer	0.000176	0.0109	CbGeAlD
Epirubicin—TOP2A—uterus—uterine cancer	0.000167	0.0104	CbGeAlD
Epirubicin—AURKA—lymph node—uterine cancer	0.000162	0.01	CbGeAlD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—uterine cancer	0.000159	0.212	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—uterine cancer	0.000159	0.212	CbGdCrCtD
Epirubicin—PLA2G4A—female reproductive system—uterine cancer	0.000158	0.00983	CbGeAlD
Epirubicin—ABCC1—myometrium—uterine cancer	0.000155	0.00964	CbGeAlD
Epirubicin—PLA2G4A—female gonad—uterine cancer	0.000144	0.00894	CbGeAlD
Epirubicin—PLA2G4A—vagina—uterine cancer	0.000143	0.00889	CbGeAlD
Epirubicin—TOP2A—female gonad—uterine cancer	0.000137	0.00849	CbGeAlD
Epirubicin—TOP2A—vagina—uterine cancer	0.000136	0.00844	CbGeAlD
Epirubicin—DHCR7—lymph node—uterine cancer	0.000135	0.0084	CbGeAlD
Epirubicin—YWHAG—lymph node—uterine cancer	0.000124	0.00771	CbGeAlD
Epirubicin—ABCC1—uterine cervix—uterine cancer	0.000121	0.0075	CbGeAlD
Epirubicin—ABCC1—decidua—uterine cancer	0.000115	0.00715	CbGeAlD
Epirubicin—ABCC1—endometrium—uterine cancer	0.000109	0.00679	CbGeAlD
Epirubicin—AURKA—Teniposide—Etoposide—uterine cancer	0.000108	0.144	CbGdCrCtD
Epirubicin—ABCC1—mammalian vulva—uterine cancer	0.000106	0.00656	CbGeAlD
Epirubicin—ABCC1—uterus—uterine cancer	0.000101	0.00625	CbGeAlD
Epirubicin—PLA2G4A—lymph node—uterine cancer	9.27e-05	0.00575	CbGeAlD
Epirubicin—TOP2A—lymph node—uterine cancer	8.8e-05	0.00546	CbGeAlD
Epirubicin—ABCC1—female gonad—uterine cancer	8.24e-05	0.00512	CbGeAlD
Epirubicin—ABCC1—vagina—uterine cancer	8.19e-05	0.00508	CbGeAlD
Epirubicin—ABCC1—lymph node—uterine cancer	5.3e-05	0.00329	CbGeAlD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—uterine cancer	5.22e-05	0.0696	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—uterine cancer	5.22e-05	0.0696	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Etoposide—uterine cancer	4.13e-05	0.0551	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—uterine cancer	4.13e-05	0.0551	CbGdCrCtD
Epirubicin—TOP2A—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	3.37e-05	0.0449	CbGdCrCtD
Epirubicin—TOP2A—Methyltestosterone—Progesterone—uterine cancer	2.94e-05	0.0392	CbGdCrCtD
Epirubicin—YWHAG—Cell Cycle—YWHAE—uterine cancer	2.02e-05	0.00132	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CDKN2B—uterine cancer	2e-05	0.00131	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2e-05	0.00131	CbGpPWpGaD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—uterine cancer	1.99e-05	0.0266	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—uterine cancer	1.99e-05	0.0266	CbGdCrCtD
Epirubicin—YWHAG—Apoptosis—CTNNB1—uterine cancer	1.98e-05	0.0013	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	1.97e-05	0.00129	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—RRM2—uterine cancer	1.97e-05	0.00129	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—RRM2—uterine cancer	1.93e-05	0.00127	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—BIRC5—uterine cancer	1.93e-05	0.00127	CbGpPWpGaD
Epirubicin—TOP2A—Norethindrone—Progesterone—uterine cancer	1.92e-05	0.0255	CbGdCrCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—KRAS—uterine cancer	1.89e-05	0.00124	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—DCN—uterine cancer	1.88e-05	0.00123	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—PIK3CA—uterine cancer	1.86e-05	0.00122	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—uterine cancer	1.85e-05	0.00121	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—uterine cancer	1.84e-05	0.00121	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—EP300—uterine cancer	1.83e-05	0.0012	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	1.83e-05	0.0012	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	1.79e-05	0.00118	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	1.79e-05	0.00118	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—uterine cancer	1.78e-05	0.00116	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CYP11A1—uterine cancer	1.77e-05	0.00116	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—KRAS—uterine cancer	1.76e-05	0.00115	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—RRM2—uterine cancer	1.76e-05	0.00115	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—uterine cancer	1.74e-05	0.00114	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—uterine cancer	1.73e-05	0.00114	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—BIRC5—uterine cancer	1.73e-05	0.00113	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—HRAS—uterine cancer	1.72e-05	0.00113	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ABCC9—uterine cancer	1.71e-05	0.00112	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN2B—uterine cancer	1.7e-05	0.00111	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKR1C3—uterine cancer	1.67e-05	0.00109	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.65e-05	0.00108	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—uterine cancer	1.64e-05	0.00107	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—PIK3CA—uterine cancer	1.62e-05	0.00106	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—uterine cancer	1.61e-05	0.00105	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—HRAS—uterine cancer	1.6e-05	0.00105	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	1.58e-05	0.00104	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—YWHAE—uterine cancer	1.58e-05	0.00103	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—HRAS—uterine cancer	1.57e-05	0.00103	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MLH1—uterine cancer	1.56e-05	0.00102	CbGpPWpGaD
Epirubicin—TOP2A—Levonorgestrel—Progesterone—uterine cancer	1.52e-05	0.0203	CbGdCrCtD
Epirubicin—YWHAG—ErbB1 downstream signaling—AKT1—uterine cancer	1.52e-05	0.000995	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDKN2B—uterine cancer	1.52e-05	0.000993	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—AKT1—uterine cancer	1.5e-05	0.000982	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—HRAS—uterine cancer	1.5e-05	0.000981	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—BIRC5—uterine cancer	1.46e-05	0.000959	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	1.46e-05	0.000958	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—uterine cancer	1.42e-05	0.000931	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	1.42e-05	0.000928	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—YWHAE—uterine cancer	1.41e-05	0.000925	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NDUFB11—uterine cancer	1.41e-05	0.000924	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—SRD5A2—uterine cancer	1.41e-05	0.000924	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—PTEN—uterine cancer	1.39e-05	0.00091	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IRF1—uterine cancer	1.39e-05	0.000908	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—AKT1—uterine cancer	1.39e-05	0.000908	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NDUFB11—uterine cancer	1.38e-05	0.000906	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SRD5A2—uterine cancer	1.38e-05	0.000906	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.34e-05	0.00088	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.34e-05	0.000878	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—AKT1—uterine cancer	1.33e-05	0.000874	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TP53—uterine cancer	1.32e-05	0.000863	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.32e-05	0.000863	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—BIRC5—uterine cancer	1.31e-05	0.000857	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—STK11—uterine cancer	1.3e-05	0.000852	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CYP19A1—uterine cancer	1.3e-05	0.000852	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—PTEN—uterine cancer	1.28e-05	0.000841	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDKN2A—uterine cancer	1.28e-05	0.000838	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.27e-05	0.000831	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.24e-05	0.000813	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—NRAS—uterine cancer	1.24e-05	0.000812	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.22e-05	0.0008	CbGpPWpGaD
Epirubicin—Sepsis—Doxorubicin—uterine cancer	1.21e-05	0.000276	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Dactinomycin—uterine cancer	1.21e-05	0.000276	CcSEcCtD
Epirubicin—Pruritus—Medroxyprogesterone Acetate—uterine cancer	1.2e-05	0.000274	CcSEcCtD
Epirubicin—Alopecia—Etoposide—uterine cancer	1.19e-05	0.000272	CcSEcCtD
Epirubicin—Vomiting—Progesterone—uterine cancer	1.19e-05	0.000272	CcSEcCtD
Epirubicin—Lymphadenopathy—Doxorubicin—uterine cancer	1.19e-05	0.000271	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	1.19e-05	0.000777	CbGpPWpGaD
Epirubicin—Rash—Progesterone—uterine cancer	1.18e-05	0.00027	CcSEcCtD
Epirubicin—Dermatitis—Progesterone—uterine cancer	1.18e-05	0.00027	CcSEcCtD
Epirubicin—Phlebitis—Doxorubicin—uterine cancer	1.18e-05	0.000268	CcSEcCtD
Epirubicin—Headache—Progesterone—uterine cancer	1.18e-05	0.000268	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.17e-05	0.000768	CbGpPWpGaD
Epirubicin—Thrombophlebitis—Doxorubicin—uterine cancer	1.17e-05	0.000267	CcSEcCtD
Epirubicin—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	1.16e-05	0.000266	CcSEcCtD
Epirubicin—Diabetes mellitus—Doxorubicin—uterine cancer	1.16e-05	0.000266	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.16e-05	0.000763	CbGpPWpGaD
Epirubicin—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	1.16e-05	0.000265	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.16e-05	0.00076	CbGpPWpGaD
Epirubicin—Hepatic function abnormal—Doxorubicin—uterine cancer	1.16e-05	0.000264	CcSEcCtD
Epirubicin—Photosensitivity—Doxorubicin—uterine cancer	1.15e-05	0.000263	CcSEcCtD
Epirubicin—Decreased appetite—Dactinomycin—uterine cancer	1.15e-05	0.000263	CcSEcCtD
Epirubicin—Dysgeusia—Etoposide—uterine cancer	1.15e-05	0.000263	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CDKN2A—uterine cancer	1.14e-05	0.00075	CbGpPWpGaD
Epirubicin—Fatigue—Dactinomycin—uterine cancer	1.14e-05	0.000261	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.14e-05	0.000749	CbGpPWpGaD
Epirubicin—Back pain—Etoposide—uterine cancer	1.14e-05	0.00026	CcSEcCtD
Epirubicin—Pain—Dactinomycin—uterine cancer	1.13e-05	0.000259	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDKN1B—uterine cancer	1.13e-05	0.000742	CbGpPWpGaD
Epirubicin—Vascular purpura—Doxorubicin—uterine cancer	1.13e-05	0.000258	CcSEcCtD
Epirubicin—Muscle spasms—Etoposide—uterine cancer	1.13e-05	0.000258	CcSEcCtD
Epirubicin—Eczema—Doxorubicin—uterine cancer	1.13e-05	0.000257	CcSEcCtD
Epirubicin—Hepatic failure—Doxorubicin—uterine cancer	1.13e-05	0.000257	CcSEcCtD
Epirubicin—Dizziness—Medroxyprogesterone Acetate—uterine cancer	1.12e-05	0.000257	CcSEcCtD
Epirubicin—Eye pain—Doxorubicin—uterine cancer	1.12e-05	0.000256	CcSEcCtD
Epirubicin—Cardiac failure congestive—Doxorubicin—uterine cancer	1.12e-05	0.000255	CcSEcCtD
Epirubicin—Nausea—Progesterone—uterine cancer	1.11e-05	0.000254	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—AKT1—uterine cancer	1.11e-05	0.000729	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SRD5A2—uterine cancer	1.11e-05	0.000724	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NDUFB11—uterine cancer	1.11e-05	0.000724	CbGpPWpGaD
Epirubicin—Renal failure acute—Doxorubicin—uterine cancer	1.1e-05	0.00025	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—PTEN—uterine cancer	1.1e-05	0.000719	CbGpPWpGaD
Epirubicin—Feeling abnormal—Dactinomycin—uterine cancer	1.09e-05	0.000249	CcSEcCtD
Epirubicin—Ill-defined disorder—Etoposide—uterine cancer	1.09e-05	0.000249	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.09e-05	0.000714	CbGpPWpGaD
Epirubicin—Anaemia—Etoposide—uterine cancer	1.09e-05	0.000248	CcSEcCtD
Epirubicin—Gastrointestinal pain—Dactinomycin—uterine cancer	1.08e-05	0.000247	CcSEcCtD
Epirubicin—Hot flush—Doxorubicin—uterine cancer	1.08e-05	0.000247	CcSEcCtD
Epirubicin—Vomiting—Medroxyprogesterone Acetate—uterine cancer	1.08e-05	0.000247	CcSEcCtD
Epirubicin—Increased appetite—Doxorubicin—uterine cancer	1.08e-05	0.000246	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.07e-05	0.000704	CbGpPWpGaD
Epirubicin—Dermatitis exfoliative—Doxorubicin—uterine cancer	1.07e-05	0.000245	CcSEcCtD
Epirubicin—Menopausal symptoms—Doxorubicin—uterine cancer	1.07e-05	0.000245	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.07e-05	0.000703	CbGpPWpGaD
Epirubicin—Rash—Medroxyprogesterone Acetate—uterine cancer	1.07e-05	0.000245	CcSEcCtD
Epirubicin—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	1.07e-05	0.000244	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—uterine cancer	1.07e-05	0.000699	CbGpPWpGaD
Epirubicin—Headache—Medroxyprogesterone Acetate—uterine cancer	1.07e-05	0.000243	CcSEcCtD
Epirubicin—Renal impairment—Doxorubicin—uterine cancer	1.06e-05	0.000243	CcSEcCtD
Epirubicin—Malaise—Etoposide—uterine cancer	1.06e-05	0.000242	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN2B—uterine cancer	1.06e-05	0.000695	CbGpPWpGaD
Epirubicin—Dermatitis bullous—Doxorubicin—uterine cancer	1.06e-05	0.000242	CcSEcCtD
Epirubicin—Vertigo—Etoposide—uterine cancer	1.06e-05	0.000241	CcSEcCtD
Epirubicin—Leukopenia—Etoposide—uterine cancer	1.05e-05	0.00024	CcSEcCtD
Epirubicin—Purpura—Doxorubicin—uterine cancer	1.05e-05	0.00024	CcSEcCtD
Epirubicin—Body temperature increased—Dactinomycin—uterine cancer	1.05e-05	0.000239	CcSEcCtD
Epirubicin—Abdominal pain—Dactinomycin—uterine cancer	1.05e-05	0.000239	CcSEcCtD
Epirubicin—Anaphylactoid reaction—Doxorubicin—uterine cancer	1.05e-05	0.000239	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—EP300—uterine cancer	1.05e-05	0.000685	CbGpPWpGaD
Epirubicin—Cardiac failure—Doxorubicin—uterine cancer	1.04e-05	0.000237	CcSEcCtD
Epirubicin—Hypoglycaemia—Doxorubicin—uterine cancer	1.04e-05	0.000237	CcSEcCtD
Epirubicin—Loss of consciousness—Etoposide—uterine cancer	1.03e-05	0.000236	CcSEcCtD
Epirubicin—Lethargy—Doxorubicin—uterine cancer	1.03e-05	0.000236	CcSEcCtD
Epirubicin—Cerebrovascular accident—Doxorubicin—uterine cancer	1.03e-05	0.000236	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.03e-05	0.000676	CbGpPWpGaD
Epirubicin—Cough—Etoposide—uterine cancer	1.03e-05	0.000234	CcSEcCtD
Epirubicin—ABCC1—Disease—AKR1B10—uterine cancer	1.03e-05	0.000672	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—BIRC5—uterine cancer	1.02e-05	0.000671	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—STAR—uterine cancer	1.02e-05	0.000668	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKR1B1—uterine cancer	1.02e-05	0.000668	CbGpPWpGaD
Epirubicin—Convulsion—Etoposide—uterine cancer	1.02e-05	0.000232	CcSEcCtD
Epirubicin—Hyponatraemia—Doxorubicin—uterine cancer	1.02e-05	0.000232	CcSEcCtD
Epirubicin—Hypertension—Etoposide—uterine cancer	1.02e-05	0.000232	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.02e-05	0.000665	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.01e-05	0.000664	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CDKN1B—uterine cancer	1.01e-05	0.000664	CbGpPWpGaD
Epirubicin—Pain in extremity—Doxorubicin—uterine cancer	1.01e-05	0.000231	CcSEcCtD
Epirubicin—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	1.01e-05	0.000231	CcSEcCtD
Epirubicin—Osteoarthritis—Doxorubicin—uterine cancer	1.01e-05	0.000231	CcSEcCtD
Epirubicin—Diplopia—Doxorubicin—uterine cancer	1.01e-05	0.000231	CcSEcCtD
Epirubicin—Nausea—Medroxyprogesterone Acetate—uterine cancer	1.01e-05	0.00023	CcSEcCtD
Epirubicin—Chest pain—Etoposide—uterine cancer	1e-05	0.000228	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—STAR—uterine cancer	1e-05	0.000655	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKR1B1—uterine cancer	1e-05	0.000655	CbGpPWpGaD
Epirubicin—Migraine—Doxorubicin—uterine cancer	9.97e-06	0.000227	CcSEcCtD
Epirubicin—Affect lability—Doxorubicin—uterine cancer	9.97e-06	0.000227	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—EP300—uterine cancer	9.95e-06	0.000652	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	9.95e-06	0.000227	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	9.9e-06	0.000648	CbGpPWpGaD
Epirubicin—Discomfort—Etoposide—uterine cancer	9.89e-06	0.000226	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	9.89e-06	0.000648	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—uterine cancer	9.8e-06	0.000642	CbGpPWpGaD
Epirubicin—Face oedema—Doxorubicin—uterine cancer	9.78e-06	0.000223	CcSEcCtD
Epirubicin—DHCR7—Metabolism—MTHFR—uterine cancer	9.77e-06	0.00064	CbGpPWpGaD
Epirubicin—Hypersensitivity—Dactinomycin—uterine cancer	9.77e-06	0.000223	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—uterine cancer	9.7e-06	0.000635	CbGpPWpGaD
Epirubicin—Confusional state—Etoposide—uterine cancer	9.68e-06	0.000221	CcSEcCtD
Epirubicin—Cardiac arrest—Doxorubicin—uterine cancer	9.63e-06	0.00022	CcSEcCtD
Epirubicin—Anaphylactic shock—Etoposide—uterine cancer	9.6e-06	0.000219	CcSEcCtD
Epirubicin—Mood swings—Doxorubicin—uterine cancer	9.6e-06	0.000219	CcSEcCtD
Epirubicin—Infection—Etoposide—uterine cancer	9.54e-06	0.000218	CcSEcCtD
Epirubicin—Ataxia—Doxorubicin—uterine cancer	9.53e-06	0.000217	CcSEcCtD
Epirubicin—Asthenia—Dactinomycin—uterine cancer	9.52e-06	0.000217	CcSEcCtD
Epirubicin—Blood creatinine increased—Doxorubicin—uterine cancer	9.49e-06	0.000216	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—AKT1—uterine cancer	9.45e-06	0.000619	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.44e-06	0.000618	CbGpPWpGaD
Epirubicin—Dehydration—Doxorubicin—uterine cancer	9.42e-06	0.000215	CcSEcCtD
Epirubicin—Thrombocytopenia—Etoposide—uterine cancer	9.4e-06	0.000214	CcSEcCtD
Epirubicin—Tachycardia—Etoposide—uterine cancer	9.37e-06	0.000214	CcSEcCtD
Epirubicin—Liver function test abnormal—Doxorubicin—uterine cancer	9.35e-06	0.000213	CcSEcCtD
Epirubicin—Skin disorder—Etoposide—uterine cancer	9.32e-06	0.000213	CcSEcCtD
Epirubicin—Dry skin—Doxorubicin—uterine cancer	9.29e-06	0.000212	CcSEcCtD
Epirubicin—Hyperhidrosis—Etoposide—uterine cancer	9.28e-06	0.000212	CcSEcCtD
Epirubicin—Orthostatic hypotension—Doxorubicin—uterine cancer	9.25e-06	0.000211	CcSEcCtD
Epirubicin—Abdominal pain upper—Doxorubicin—uterine cancer	9.25e-06	0.000211	CcSEcCtD
Epirubicin—Hypokalaemia—Doxorubicin—uterine cancer	9.22e-06	0.00021	CcSEcCtD
Epirubicin—Breast disorder—Doxorubicin—uterine cancer	9.15e-06	0.000209	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—BIRC5—uterine cancer	9.15e-06	0.0006	CbGpPWpGaD
Epirubicin—Anorexia—Etoposide—uterine cancer	9.15e-06	0.000209	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	9.12e-06	0.000208	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	9.12e-06	0.000208	CcSEcCtD
Epirubicin—Diarrhoea—Dactinomycin—uterine cancer	9.08e-06	0.000207	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—uterine cancer	9.07e-06	0.000594	CbGpPWpGaD
Epirubicin—Nasopharyngitis—Doxorubicin—uterine cancer	9.06e-06	0.000207	CcSEcCtD
Epirubicin—PLA2G4A—Phospholipid metabolism—PIK3CA—uterine cancer	9.06e-06	0.000593	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKR1B10—uterine cancer	9e-06	0.000589	CbGpPWpGaD
Epirubicin—Hypotension—Etoposide—uterine cancer	8.97e-06	0.000205	CcSEcCtD
Epirubicin—Gastritis—Doxorubicin—uterine cancer	8.97e-06	0.000205	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	8.94e-06	0.000586	CbGpPWpGaD
Epirubicin—Muscular weakness—Doxorubicin—uterine cancer	8.93e-06	0.000204	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Doxorubicin—uterine cancer	8.93e-06	0.000204	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—EP300—uterine cancer	8.9e-06	0.000583	CbGpPWpGaD
Epirubicin—Abdominal distension—Doxorubicin—uterine cancer	8.81e-06	0.000201	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	8.77e-06	0.000575	CbGpPWpGaD
Epirubicin—Dysphagia—Doxorubicin—uterine cancer	8.76e-06	0.0002	CcSEcCtD
Epirubicin—Influenza—Doxorubicin—uterine cancer	8.76e-06	0.0002	CcSEcCtD
Epirubicin—Asthma—Doxorubicin—uterine cancer	8.76e-06	0.0002	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—uterine cancer	8.67e-06	0.000568	CbGpPWpGaD
Epirubicin—Eosinophilia—Doxorubicin—uterine cancer	8.67e-06	0.000198	CcSEcCtD
Epirubicin—Paraesthesia—Etoposide—uterine cancer	8.62e-06	0.000197	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.61e-06	0.000564	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN1B—uterine cancer	8.59e-06	0.000563	CbGpPWpGaD
Epirubicin—Pancreatitis—Doxorubicin—uterine cancer	8.58e-06	0.000196	CcSEcCtD
Epirubicin—Dyspnoea—Etoposide—uterine cancer	8.56e-06	0.000195	CcSEcCtD
Epirubicin—Somnolence—Etoposide—uterine cancer	8.53e-06	0.000195	CcSEcCtD
Epirubicin—Angina pectoris—Doxorubicin—uterine cancer	8.53e-06	0.000195	CcSEcCtD
Epirubicin—ABCC1—Disease—RNF43—uterine cancer	8.5e-06	0.000557	CbGpPWpGaD
Epirubicin—Vomiting—Dactinomycin—uterine cancer	8.43e-06	0.000192	CcSEcCtD
Epirubicin—Bronchitis—Doxorubicin—uterine cancer	8.42e-06	0.000192	CcSEcCtD
Epirubicin—Rash—Dactinomycin—uterine cancer	8.36e-06	0.000191	CcSEcCtD
Epirubicin—Decreased appetite—Etoposide—uterine cancer	8.35e-06	0.00019	CcSEcCtD
Epirubicin—Pancytopenia—Doxorubicin—uterine cancer	8.32e-06	0.00019	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Etoposide—uterine cancer	8.29e-06	0.000189	CcSEcCtD
Epirubicin—Fatigue—Etoposide—uterine cancer	8.28e-06	0.000189	CcSEcCtD
Epirubicin—Constipation—Etoposide—uterine cancer	8.21e-06	0.000187	CcSEcCtD
Epirubicin—Pain—Etoposide—uterine cancer	8.21e-06	0.000187	CcSEcCtD
Epirubicin—Dysuria—Doxorubicin—uterine cancer	8.19e-06	0.000187	CcSEcCtD
Epirubicin—Neutropenia—Doxorubicin—uterine cancer	8.19e-06	0.000187	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Doxorubicin—uterine cancer	8.14e-06	0.000186	CcSEcCtD
Epirubicin—Pollakiuria—Doxorubicin—uterine cancer	8.09e-06	0.000185	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	8.06e-06	0.000528	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—POLD1—uterine cancer	8e-06	0.000524	CbGpPWpGaD
Epirubicin—Photosensitivity reaction—Doxorubicin—uterine cancer	7.99e-06	0.000182	CcSEcCtD
Epirubicin—ABCC1—Metabolism—AKR1B1—uterine cancer	7.99e-06	0.000524	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—STAR—uterine cancer	7.99e-06	0.000524	CbGpPWpGaD
Epirubicin—Weight increased—Doxorubicin—uterine cancer	7.97e-06	0.000182	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	7.95e-06	0.000521	CbGpPWpGaD
Epirubicin—Weight decreased—Doxorubicin—uterine cancer	7.92e-06	0.000181	CcSEcCtD
Epirubicin—Feeling abnormal—Etoposide—uterine cancer	7.91e-06	0.00018	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.9e-06	0.000517	CbGpPWpGaD
Epirubicin—Hyperglycaemia—Doxorubicin—uterine cancer	7.9e-06	0.00018	CcSEcCtD
Epirubicin—Nausea—Dactinomycin—uterine cancer	7.88e-06	0.00018	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—uterine cancer	7.85e-06	0.000179	CcSEcCtD
Epirubicin—Gastrointestinal pain—Etoposide—uterine cancer	7.85e-06	0.000179	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—POLD1—uterine cancer	7.85e-06	0.000514	CbGpPWpGaD
Epirubicin—Drowsiness—Doxorubicin—uterine cancer	7.81e-06	0.000178	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—uterine cancer	7.81e-06	0.000178	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—uterine cancer	7.81e-06	0.000178	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.8e-06	0.000511	CbGpPWpGaD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	7.74e-06	0.000177	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN1B—uterine cancer	7.68e-06	0.000503	CbGpPWpGaD
Epirubicin—Renal failure—Doxorubicin—uterine cancer	7.67e-06	0.000175	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—uterine cancer	7.65e-06	0.000175	CcSEcCtD
Epirubicin—Urticaria—Etoposide—uterine cancer	7.63e-06	0.000174	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—uterine cancer	7.61e-06	0.000174	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—uterine cancer	7.61e-06	0.000174	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	7.6e-06	0.000498	CbGpPWpGaD
Epirubicin—Body temperature increased—Etoposide—uterine cancer	7.59e-06	0.000173	CcSEcCtD
Epirubicin—Abdominal pain—Etoposide—uterine cancer	7.59e-06	0.000173	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—uterine cancer	7.59e-06	0.000173	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—uterine cancer	7.59e-06	0.000173	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—EP300—uterine cancer	7.54e-06	0.000494	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKR1C1—uterine cancer	7.49e-06	0.00049	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—uterine cancer	7.49e-06	0.00049	CbGpPWpGaD
Epirubicin—Sweating—Doxorubicin—uterine cancer	7.48e-06	0.000171	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—RNF43—uterine cancer	7.45e-06	0.000488	CbGpPWpGaD
Epirubicin—Haematuria—Doxorubicin—uterine cancer	7.44e-06	0.00017	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—uterine cancer	7.38e-06	0.000168	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—uterine cancer	7.36e-06	0.000168	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—AKR1C1—uterine cancer	7.34e-06	0.000481	CbGpPWpGaD
Epirubicin—Sinusitis—Doxorubicin—uterine cancer	7.32e-06	0.000167	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—uterine cancer	7.29e-06	0.000166	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—uterine cancer	7.13e-06	0.000163	CcSEcCtD
Epirubicin—Hypersensitivity—Etoposide—uterine cancer	7.07e-06	0.000161	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—uterine cancer	7.04e-06	0.000161	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—uterine cancer	7.03e-06	0.00016	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—uterine cancer	7.01e-06	0.00016	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—uterine cancer	7.01e-06	0.00016	CcSEcCtD
Epirubicin—ABCC1—Disease—AKR1C1—uterine cancer	7e-06	0.000459	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	6.98e-06	0.000457	CbGpPWpGaD
Epirubicin—Hypoaesthesia—Doxorubicin—uterine cancer	6.97e-06	0.000159	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—uterine cancer	6.96e-06	0.000159	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—uterine cancer	6.92e-06	0.000158	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—uterine cancer	6.9e-06	0.000157	CcSEcCtD
Epirubicin—Asthenia—Etoposide—uterine cancer	6.89e-06	0.000157	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—uterine cancer	6.89e-06	0.000157	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—uterine cancer	6.87e-06	0.000157	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—INHBA—uterine cancer	6.82e-06	0.000447	CbGpPWpGaD
Epirubicin—Pruritus—Etoposide—uterine cancer	6.79e-06	0.000155	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	6.78e-06	0.000444	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	6.75e-06	0.000443	CbGpPWpGaD
Epirubicin—Visual impairment—Doxorubicin—uterine cancer	6.75e-06	0.000154	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—EP300—uterine cancer	6.74e-06	0.000442	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—RRM2—uterine cancer	6.67e-06	0.000437	CbGpPWpGaD
Epirubicin—Erythema multiforme—Doxorubicin—uterine cancer	6.63e-06	0.000151	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.58e-06	0.000431	CbGpPWpGaD
Epirubicin—Diarrhoea—Etoposide—uterine cancer	6.57e-06	0.00015	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—uterine cancer	6.55e-06	0.000149	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—RRM2—uterine cancer	6.54e-06	0.000429	CbGpPWpGaD
Epirubicin—Tinnitus—Doxorubicin—uterine cancer	6.53e-06	0.000149	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—uterine cancer	6.5e-06	0.000148	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—uterine cancer	6.5e-06	0.000148	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—DCN—uterine cancer	6.48e-06	0.000424	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TP53—uterine cancer	6.37e-06	0.000417	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—uterine cancer	6.36e-06	0.000145	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—DCN—uterine cancer	6.35e-06	0.000416	CbGpPWpGaD
Epirubicin—Dizziness—Etoposide—uterine cancer	6.35e-06	0.000145	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—uterine cancer	6.33e-06	0.000144	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—uterine cancer	6.32e-06	0.000144	CcSEcCtD
Epirubicin—Chills—Doxorubicin—uterine cancer	6.29e-06	0.000143	CcSEcCtD
Epirubicin—ABCC1—Metabolism—POLD1—uterine cancer	6.27e-06	0.000411	CbGpPWpGaD
Epirubicin—Arrhythmia—Doxorubicin—uterine cancer	6.26e-06	0.000143	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	6.21e-06	0.000407	CbGpPWpGaD
Epirubicin—Alopecia—Doxorubicin—uterine cancer	6.19e-06	0.000141	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—uterine cancer	6.14e-06	0.00014	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—AKR1C1—uterine cancer	6.14e-06	0.000402	CbGpPWpGaD
Epirubicin—Vomiting—Etoposide—uterine cancer	6.1e-06	0.000139	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CYP11A1—uterine cancer	6.1e-06	0.0004	CbGpPWpGaD
Epirubicin—Erythema—Doxorubicin—uterine cancer	6.1e-06	0.000139	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—uterine cancer	6.1e-06	0.000139	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN2A—uterine cancer	6.06e-06	0.000397	CbGpPWpGaD
Epirubicin—ABCC1—Disease—DCN—uterine cancer	6.06e-06	0.000397	CbGpPWpGaD
Epirubicin—Rash—Etoposide—uterine cancer	6.05e-06	0.000138	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—uterine cancer	6.05e-06	0.000138	CcSEcCtD
Epirubicin—Headache—Etoposide—uterine cancer	6.01e-06	0.000137	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—uterine cancer	6.01e-06	0.000137	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	6.01e-06	0.000394	CbGpPWpGaD
Epirubicin—Tension—Doxorubicin—uterine cancer	5.99e-06	0.000137	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—CYP11A1—uterine cancer	5.98e-06	0.000392	CbGpPWpGaD
Epirubicin—Dysgeusia—Doxorubicin—uterine cancer	5.97e-06	0.000136	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—uterine cancer	5.93e-06	0.000135	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—uterine cancer	5.9e-06	0.000135	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—uterine cancer	5.87e-06	0.000134	CcSEcCtD
Epirubicin—ABCC1—Metabolism—AKR1C1—uterine cancer	5.87e-06	0.000384	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKR1C3—uterine cancer	5.76e-06	0.000378	CbGpPWpGaD
Epirubicin—Vision blurred—Doxorubicin—uterine cancer	5.75e-06	0.000131	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.7e-06	0.000374	CbGpPWpGaD
Epirubicin—Nausea—Etoposide—uterine cancer	5.7e-06	0.00013	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—uterine cancer	5.66e-06	0.000129	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—AKR1C3—uterine cancer	5.65e-06	0.00037	CbGpPWpGaD
Epirubicin—Anaemia—Doxorubicin—uterine cancer	5.64e-06	0.000129	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—uterine cancer	5.61e-06	0.000128	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—uterine cancer	5.5e-06	0.000125	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—uterine cancer	5.48e-06	0.000125	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—uterine cancer	5.47e-06	0.000125	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—uterine cancer	5.46e-06	0.000125	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PTEN—uterine cancer	5.44e-06	0.000356	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKR1C3—uterine cancer	5.39e-06	0.000353	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—uterine cancer	5.39e-06	0.000123	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN1B—uterine cancer	5.37e-06	0.000352	CbGpPWpGaD
Epirubicin—Loss of consciousness—Doxorubicin—uterine cancer	5.36e-06	0.000122	CcSEcCtD
Epirubicin—Cough—Doxorubicin—uterine cancer	5.32e-06	0.000121	CcSEcCtD
Epirubicin—Convulsion—Doxorubicin—uterine cancer	5.29e-06	0.000121	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—EP300—uterine cancer	5.27e-06	0.000346	CbGpPWpGaD
Epirubicin—Hypertension—Doxorubicin—uterine cancer	5.27e-06	0.00012	CcSEcCtD
Epirubicin—ABCC1—Disease—HMGA1—uterine cancer	5.25e-06	0.000344	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—RRM2—uterine cancer	5.23e-06	0.000342	CbGpPWpGaD
Epirubicin—Chest pain—Doxorubicin—uterine cancer	5.19e-06	0.000118	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—uterine cancer	5.19e-06	0.000118	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—uterine cancer	5.19e-06	0.000118	CcSEcCtD
Epirubicin—DHCR7—Metabolism—EP300—uterine cancer	5.19e-06	0.00034	CbGpPWpGaD
Epirubicin—Anxiety—Doxorubicin—uterine cancer	5.18e-06	0.000118	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.16e-06	0.000118	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—uterine cancer	5.13e-06	0.000117	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—uterine cancer	5.08e-06	0.000116	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—uterine cancer	5.08e-06	0.000333	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—DCN—uterine cancer	5.07e-06	0.000332	CbGpPWpGaD
Epirubicin—Confusional state—Doxorubicin—uterine cancer	5.02e-06	0.000115	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—uterine cancer	4.98e-06	0.000114	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—uterine cancer	4.98e-06	0.000114	CcSEcCtD
Epirubicin—Infection—Doxorubicin—uterine cancer	4.95e-06	0.000113	CcSEcCtD
Epirubicin—Shock—Doxorubicin—uterine cancer	4.9e-06	0.000112	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—uterine cancer	4.88e-06	0.000111	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—uterine cancer	4.88e-06	0.000111	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—uterine cancer	4.86e-06	0.000111	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—uterine cancer	4.84e-06	0.00011	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TP53—uterine cancer	4.83e-06	0.000316	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Doxorubicin—uterine cancer	4.81e-06	0.00011	CcSEcCtD
Epirubicin—ABCC1—Disease—FBXW7—uterine cancer	4.81e-06	0.000315	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP11A1—uterine cancer	4.78e-06	0.000313	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—uterine cancer	4.75e-06	0.000108	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—AKR1C3—uterine cancer	4.73e-06	0.00031	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—EP300—uterine cancer	4.72e-06	0.000309	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—uterine cancer	4.65e-06	0.000106	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PGR—uterine cancer	4.6e-06	0.000302	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.54e-06	0.000103	CcSEcCtD
Epirubicin—ABCC1—Metabolism—AKR1C3—uterine cancer	4.52e-06	0.000296	CbGpPWpGaD
Epirubicin—Insomnia—Doxorubicin—uterine cancer	4.5e-06	0.000103	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—STK11—uterine cancer	4.49e-06	0.000294	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP19A1—uterine cancer	4.49e-06	0.000294	CbGpPWpGaD
Epirubicin—Paraesthesia—Doxorubicin—uterine cancer	4.47e-06	0.000102	CcSEcCtD
Epirubicin—Dyspnoea—Doxorubicin—uterine cancer	4.44e-06	0.000101	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—uterine cancer	4.43e-06	0.000101	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—STK11—uterine cancer	4.4e-06	0.000288	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP19A1—uterine cancer	4.4e-06	0.000288	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—YWHAE—uterine cancer	4.39e-06	0.000288	CbGpPWpGaD
Epirubicin—Dyspepsia—Doxorubicin—uterine cancer	4.38e-06	0.0001	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—EP300—uterine cancer	4.33e-06	0.000284	CbGpPWpGaD
Epirubicin—Decreased appetite—Doxorubicin—uterine cancer	4.33e-06	9.87e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.3e-06	9.81e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—uterine cancer	4.29e-06	9.79e-05	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—uterine cancer	4.26e-06	9.71e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—uterine cancer	4.26e-06	9.71e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FBXW7—uterine cancer	4.21e-06	0.000276	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.13e-06	0.000271	CbGpPWpGaD
Epirubicin—Feeling abnormal—Doxorubicin—uterine cancer	4.1e-06	9.36e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—uterine cancer	4.1e-06	0.000269	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Doxorubicin—uterine cancer	4.07e-06	9.29e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—NRAS—uterine cancer	4.05e-06	0.000265	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—uterine cancer	3.96e-06	9.02e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.94e-06	0.000258	CbGpPWpGaD
Epirubicin—Body temperature increased—Doxorubicin—uterine cancer	3.94e-06	8.98e-05	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—uterine cancer	3.94e-06	8.98e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CA—uterine cancer	3.84e-06	0.000251	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN2B—uterine cancer	3.77e-06	0.000247	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STK11—uterine cancer	3.68e-06	0.000241	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—uterine cancer	3.67e-06	8.37e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL2—uterine cancer	3.66e-06	0.00024	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—uterine cancer	3.57e-06	8.15e-05	CcSEcCtD
Epirubicin—Pruritus—Doxorubicin—uterine cancer	3.52e-06	8.04e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP19A1—uterine cancer	3.52e-06	0.00023	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—STK11—uterine cancer	3.52e-06	0.00023	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—uterine cancer	3.49e-06	0.000228	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SOCS3—uterine cancer	3.45e-06	0.000226	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SMAD3—uterine cancer	3.44e-06	0.000225	CbGpPWpGaD
Epirubicin—Diarrhoea—Doxorubicin—uterine cancer	3.41e-06	7.77e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—uterine cancer	3.38e-06	0.000221	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—MTHFR—uterine cancer	3.37e-06	0.000221	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—MTHFR—uterine cancer	3.31e-06	0.000217	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.3e-06	0.000216	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN2B—uterine cancer	3.3e-06	0.000216	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—uterine cancer	3.29e-06	7.51e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—FGFR2—uterine cancer	3.28e-06	0.000215	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1R—uterine cancer	3.2e-06	0.00021	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—uterine cancer	3.2e-06	0.00021	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—uterine cancer	3.17e-06	7.22e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—MTHFR—uterine cancer	3.16e-06	0.000207	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.15e-06	0.000206	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—uterine cancer	3.14e-06	7.16e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—uterine cancer	3.14e-06	7.15e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—AKT1—uterine cancer	3.13e-06	0.000205	CbGpPWpGaD
Epirubicin—Headache—Doxorubicin—uterine cancer	3.12e-06	7.12e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—TP53—uterine cancer	3.1e-06	0.000203	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMAD3—uterine cancer	3.01e-06	0.000197	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—uterine cancer	2.96e-06	0.000194	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—uterine cancer	2.96e-06	6.75e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.92e-06	0.000191	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—uterine cancer	2.9e-06	0.00019	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR2—uterine cancer	2.87e-06	0.000188	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—MTHFR—uterine cancer	2.64e-06	0.000173	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—uterine cancer	2.62e-06	0.000171	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ESR1—uterine cancer	2.46e-06	0.000161	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.33e-06	0.000153	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—uterine cancer	2.32e-06	0.000152	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCL2—uterine cancer	2.16e-06	0.000142	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB2—uterine cancer	2.06e-06	0.000135	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—uterine cancer	2e-06	0.000131	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1B—uterine cancer	1.91e-06	0.000125	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—uterine cancer	1.88e-06	0.000123	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—uterine cancer	1.84e-06	0.000121	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—uterine cancer	1.84e-06	0.00012	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB2—uterine cancer	1.8e-06	0.000118	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—uterine cancer	1.8e-06	0.000118	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—EP300—uterine cancer	1.79e-06	0.000117	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—uterine cancer	1.76e-06	0.000115	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—EP300—uterine cancer	1.76e-06	0.000115	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—uterine cancer	1.71e-06	0.000112	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—uterine cancer	1.7e-06	0.000111	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EP300—uterine cancer	1.67e-06	0.00011	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1B—uterine cancer	1.67e-06	0.00011	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—uterine cancer	1.58e-06	0.000103	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—uterine cancer	1.57e-06	0.000103	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—uterine cancer	1.54e-06	0.000101	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—uterine cancer	1.5e-06	9.84e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—uterine cancer	1.47e-06	9.63e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EP300—uterine cancer	1.47e-06	9.62e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—EP300—uterine cancer	1.4e-06	9.19e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—uterine cancer	1.39e-06	9.11e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—uterine cancer	1.37e-06	9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—uterine cancer	1.35e-06	8.83e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—uterine cancer	1.32e-06	8.67e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—uterine cancer	1.3e-06	8.51e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—uterine cancer	1.24e-06	8.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—uterine cancer	1.18e-06	7.74e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—uterine cancer	1.15e-06	7.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—uterine cancer	1.09e-06	7.11e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—uterine cancer	1.08e-06	7.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—uterine cancer	1.06e-06	6.95e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—uterine cancer	1.05e-06	6.88e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—uterine cancer	1.04e-06	6.8e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—uterine cancer	1.01e-06	6.63e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—uterine cancer	1e-06	6.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—uterine cancer	8.87e-07	5.81e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—uterine cancer	8.47e-07	5.55e-05	CbGpPWpGaD
